DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

 

Cardiology Homepage

Edwards Lifesciences’ CENTERA valve demonstrates excellent clinical outcomes in new study CE mark expected in fourth quarter

Continuity of care is more important than speed in the case of chronic heart failure New research shows improved outcomes for patients returned to same hospital

The latest news in defibrillators, patient monitoring and biomedical testing equipment Devices that underscore the importance of patient safety

IBM and Sutter Health partner to predict heart failure risk using EHR data Using AI to stop cardiovascular events before they happen

Study reveals low adherence to nuclear cardiology dose reduction guidelines Most sites implemented less than half of metrics

One in five AEDs in four regions failed at least one phase of testing Five percent wouldn't even turn on at all

GE and Lantheus extend flurpiridaz F 18 agreement to 2020 Companies committed to coronary PET agent development and commercialization

U.S. and Chinese researchers work to standardize MR stroke protocols with 3-D model Better understanding ICAD with the aid of high-res imaging

Siemens partners with Ebit for Suitestensa cardio IT system Agreement initially in Germany, but with plans to expand to other countries

BIOTRONIK launches its Plexa ProMRI MR-conditional tachycardia lead Smallest of its kind

Boston Scientific's EMBLEM
MRI S-ICD System

Boston Scientific's S-ICD system found to have low complication rate

by Lauren Dubinsky , Senior Reporter
In the largest study of its kind, Boston Scientific’s Subcutaneous Implantable Defibrillator System demonstrated a high success rate and low complication rate in treating sicker patients and those who would usually get a transvenous ICD.

The data was presented last Thursday at the Heart Rhythm Society’s 38th Annual Scientific Sessions in Chicago.

Story Continues Below Advertisement

CT, MRI, NM, SPECT/CT, PET & PET/CT service, refurbished systems and parts

Accelerate your ROI with our Black Diamond Certified refurbished systems. One year warranty - ISO 13485 Certified - FDA registered - Over 65k parts in inventory DOTmed Certified



The system became the world’s first commercially available S-ICD for treating patients at risk of sudden cardiac arrest when it received FDA approval in September 2012.

The device doesn’t require leads to be placed inside the heart.

The non-randomized study, initiated after the system received FDA approval, included 1,637 patients who were implanted with the device at 83 medical centers in the U.S. Almost two-thirds of them were primary prevention patients with a low ejection fraction, which refers to how well their ventricle pumped blood with each heartbeat.

In addition, over half of the patients suffered comorbidities, including heart failure and hypertension, and more than 13 percent were on dialysis for end-stage renal disease.

The research revealed that the S-ICD system effectively terminated life-threatening arrhythmias in 98.7 percent of the patients. Thirty days after the procedure, the complication-free rate was 96.2 percent.

"Beyond the positive clinical outcomes, we are also seeing advancements in procedural techniques as physician experience and confidence continue to build," Dr. Kenneth Stein, senior vice president and chief medical officer of global health policy and rhythm management at Boston Scientific, said in a statement.

Physicians are now capable of implanting over half of the devices with two surgical incisions instead of the standard approach, which involves three incisions. They can also avoid the use of general anesthesia in more than one-third of patients.

Last month, Boston Scientific initiated a global study that will evaluate its latest generation device, the EMBLEM MRI S-ICD System. The Multicenter Automatic Defibrillator Implantation Trial with Subcutaneous Implantable Cardioverter Defibrillator will evaluate the survival benefit of patients treated with the device who are 65 and older with a history of heart attack, diabetes, and moderately reduced left ventricular ejection fraction.

The EMBLEM MRI S-ICD System received FDA approval in August 2016 for patients at risk of sudden cardiac arrest. It doesn’t touch the heart and vasculature, which reduces the risk of complications associated with conventional TV-ICD leads.

Cardiology Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2017 DOTmed.com, Inc.
ALL RIGHTS RESERVED